223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide

Carles, J.Alonso, T.Mellado Gonzalez, B.Mendez Vidal, M. J.Vazquez Estevez, S.Gonzalez del Alba, A.Piulats, J. M.Borrega Garcia, P.Gallardo, E.Morales Barrera, R.Paredes, P.Reig, O.Garcias de Espana, C.Collado, R.Bonfill, T.Suarez, C.Malfettone, A.Garde, J.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/25496en223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamideconference outputopen access10.1016/j.annonc.2020.08.8981569-8041http://www.annalsofoncology.org/article/S0923753420408944/pdf573469100636